Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pavmed Inc (NQ: PAVM )

1.055 +0.025 (+2.43%)
Streaming Delayed Price Updated: 1:07 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 726,172
Open 1.050
Bid (Size) 1.050 (42)
Ask (Size) 1.060 (5)
Prev. Close 1.030
Today's Range 1.020 - 1.080
52wk Range 0.9400 - 9.700
Shares Outstanding 87,974,146
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're starting off the final day of the workweek with an overview of the biggest pre-market stock movers for Friday! 
Via InvestorPlace

Performance

YTD
-57.80%
-57.80%
1 Month
+6.57%
+6.57%
3 Month
-37.20%
-37.20%
6 Month
-78.47%
-78.47%
1 Year
-73.29%
-73.29%

More News

Read More
PAVmed: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Earnings Scheduled For May 12, 2022
Via Benzinga
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
61 Biggest Movers From Yesterday
Via Benzinga
PAVmed to Hold a Business Update Conference Call on May 12, 2022
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
From Lucid Diagnostics Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Via Benzinga
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
From Lucid Diagnostics Inc.
Via Business Wire
Earnings Preview: PAVmed
Via Benzinga
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
From Lucid Diagnostics Inc.
Via Business Wire
Earnings Scheduled For March 29, 2022
Via Benzinga
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System
Via Benzinga
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
From PAVmed Inc.
Via Business Wire
64 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.